Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

121 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Antimicrobial activity, membrane interaction and structural features of short arginine-rich antimicrobial peptides.
Agrillo B, Porritiello A, Gratino L, Balestrieri M, Proroga YT, Mancusi A, Cozzi L, Vicenza T, Dardano P, Miranda B, Escribá PV, Gogliettino M, Palmieri G. Agrillo B, et al. Among authors: escriba pv. Front Microbiol. 2023 Oct 5;14:1244325. doi: 10.3389/fmicb.2023.1244325. eCollection 2023. Front Microbiol. 2023. PMID: 37869668 Free PMC article.
Editorial: Metabolic modulation of cellular function.
Kakhlon O, Saada A, Escriba PV. Kakhlon O, et al. Among authors: escriba pv. Front Cell Dev Biol. 2024 Mar 18;12:1395922. doi: 10.3389/fcell.2024.1395922. eCollection 2024. Front Cell Dev Biol. 2024. PMID: 38562142 Free PMC article. No abstract available.
Corrigendum: Editorial: Metabolic modulation of cellular function.
Kakhlon O, Saada A, Escriba PV. Kakhlon O, et al. Among authors: escriba pv. Front Cell Dev Biol. 2024 Apr 11;12:1403128. doi: 10.3389/fcell.2024.1403128. eCollection 2024. Front Cell Dev Biol. 2024. PMID: 38665431 Free PMC article.
Randomised, double-blind, placebo-controlled, parallel-group, multicentric, phase IIA clinical trial for evaluating the safety, tolerability, and therapeutic efficacy of daily oral administration of NFX88 to treat neuropathic pain in individuals with spinal cord injury.
Escribá PV, Gil-Agudo ÁM, Vidal Samsó J, Sánchez-Raya J, Salvador-de la Barrera S, Soto-León V, León-Álvarez N, Méndez Ferrer B, Membrilla-Mesa MD, Redondo Galán C, Benito-Penalva J, Montoto-Marqués A, Medel Rebollo J, Palazón García R, Gutiérrez Henares F, Miralles M, Torres M, Nieto-Librero AB, García Marco D, Gómez C, Jimeno D, Oliviero A. Escribá PV, et al. Spinal Cord. 2024 Aug;62(8):454-467. doi: 10.1038/s41393-024-01006-4. Epub 2024 Jun 19. Spinal Cord. 2024. PMID: 38898145 Free PMC article. Clinical Trial.
A Phase 1/2A trial of idroxioleic acid: first-in-class sphingolipid regulator and glioma cell autophagy inducer with antitumor activity in refractory glioma.
Lopez J, Lai-Kwon J, Molife R, Welsh L, Tunariu N, Roda D, Fernández-García P, Lladó V, McNicholl AG, Rosselló CA, Taylor RJ, Azaro A, Rodón J, Sludden J, Veal GJ, Plummer R, Urruticoechea A, Lahuerta A, Mujika K, Escribá PV. Lopez J, et al. Among authors: escriba pv. Br J Cancer. 2023 Sep;129(5):811-818. doi: 10.1038/s41416-023-02356-1. Epub 2023 Jul 24. Br J Cancer. 2023. PMID: 37488446 Free PMC article. Clinical Trial.
121 results